Skip to main content
Premium Trial:

Request an Annual Quote

J&J R&D Division Licenses Simcyp's ADME Simulator

NEW YORK (GenomeWeb News) – Johnson & Johnson’s drug research division has licensed Simcyp’s drug modeling and simulation platform, the UK-based firm said today.
 
Through the license, Johnson & Johnson Pharmaceutical Research and Development will provide access to Simcyp’s population-based Simulator and pediatric module to its global R&D teams for a period of three years. The Simcyp platform provides modeling and simulation of drug absorption, distribution, metabolism, and elimination in virtual populations.
 
The Sheffield-based company said its platform allows researchers to identify individuals who are at extreme risk for adverse drug reactions, and allows for the minimization of drug exposure to human and animal volunteers. The platform also can help assess and manage potential interactions between drugs before human studies begin, the company said.
 
Financial terms of the agreement were not released.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.